tiprankstipranks
Merck KGaA Sponsored ADR (MKKGY)
OTHER OTC:MKKGY
US Market
Want to see MKKGY full AI Analyst Report?

Merck KGaA Sponsored ADR (MKKGY) Price & Analysis

4 Followers

MKKGY Stock Chart & Stats

$29.80
--
Market closed
$29.80
--

Bulls Say, Bears Say

Bulls Say
Diversified, Recurring Revenue ModelMerck's three-segment structure (Life Science, Healthcare, Electronics) and Life Science's recurring consumables create a diversified revenue base. This structural mix reduces dependence on any single product cycle, smoothing cash flow and supporting steady investment and resilience over the medium term.
Consistent Cash Generation And MarginsThe company has delivered repeatable operating cash flow and free cash flow (rebound in 2024 and further growth in 2025) alongside historically healthy margins. Durable FCF supports continued capex, M&A, and a stable dividend policy, underpinning financial flexibility over the next several quarters.
Structural Growth In Semiconductor MaterialsElectronics' semiconductor materials achieved high-single-digit organic growth and Merck opened a €500m Semiconductor Solutions megasite in Taiwan. These strategic investments align with secular AI/advanced-node demand and materially strengthen long-term exposure to higher-value semiconductor content.
Bears Say
Loss Of Mavenclad U.S. ExclusivityThe assumed cessation of U.S. Mavenclad sales from March 2026 signals a structural lifecycle decline for a material product. With roughly half of Mavenclad sales historically in the U.S., this creates a persistent healthcare revenue and margin gap that must be offset by new launches, business development, or portfolio restructuring over the medium term.
Choppy Revenue And Profit Step-downTop-line volatility and a decline in net income to ~€2.5bn in 2025 indicate weaker organic momentum and reduced earnings reliability. This inconsistent growth profile limits planning visibility, increases reliance on M&A and product launches, and raises execution risk for returning the company to steady organic expansion.
Rising Debt Weakens Balance Sheet TrendAn increase in reported total debt in 2025 alongside declining equity reduces financial flexibility. Higher leverage constrains the firm's ability to fund R&D, capex and deals without elevating refinancing or rating risks, particularly if cash generation softens amid product lifecycle headwinds and FX volatility.

MKKGY FAQ

What was Merck KGaA Sponsored ADR’s price range in the past 12 months?
Merck KGaA Sponsored ADR lowest stock price was $23.82 and its highest was $30.70 in the past 12 months.
    What is Merck KGaA Sponsored ADR’s market cap?
    Merck KGaA Sponsored ADR’s market cap is $57.72B.
      When is Merck KGaA Sponsored ADR’s upcoming earnings report date?
      Merck KGaA Sponsored ADR’s upcoming earnings report date is May 14, 2026 which is in 3 days.
        How were Merck KGaA Sponsored ADR’s earnings last quarter?
        Merck KGaA Sponsored ADR released its earnings results on Mar 05, 2026. The company reported $0.435 earnings per share for the quarter, missing the consensus estimate of $0.459 by -$0.024.
          Is Merck KGaA Sponsored ADR overvalued?
          According to Wall Street analysts Merck KGaA Sponsored ADR’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Merck KGaA Sponsored ADR pay dividends?
            Merck KGaA Sponsored ADR pays a Annually dividend of $0.5 which represents an annual dividend yield of 1.77%. See more information on Merck KGaA Sponsored ADR dividends here
              What is Merck KGaA Sponsored ADR’s EPS estimate?
              Merck KGaA Sponsored ADR’s EPS estimate is 0.46.
                How many shares outstanding does Merck KGaA Sponsored ADR have?
                Merck KGaA Sponsored ADR has 646,211,240 shares outstanding.
                  What happened to Merck KGaA Sponsored ADR’s price movement after its last earnings report?
                  Merck KGaA Sponsored ADR reported an EPS of $0.435 in its last earnings report, missing expectations of $0.459. Following the earnings report the stock price went down -8.457%.
                    Which hedge fund is a major shareholder of Merck KGaA Sponsored ADR?
                    Currently, no hedge funds are holding shares in MKKGY
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Merck KGaA Sponsored ADR Stock Smart Score

                      5
                      Neutral
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10

                      Company Description

                      Merck KGaA Sponsored ADR

                      Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

                      Merck KGaA Sponsored ADR (MKKGY) Earnings & Revenues

                      MKKGY Company Deck

                      MKKGY Earnings Call

                      Q4 2026
                      0:00 / 0:00
                      Earnings Call Sentiment|Neutral
                      The call presented a mixed but resilient picture: Merck delivered on 2025 guidance, achieved organic EBITDA growth, and showed sector-level recoveries (notably Life Science and semiconductor materials) and strategic progress through M&A and site investments. However, meaningful headwinds remain — significant foreign exchange pressures, the imminent U.S. loss of Mavenclad exclusivity, near-term weakness in the Electronics DS&S business, and regulatory/portfolio uncertainties. Management’s proactive strategic moves and solid cash generation balance these risks, leaving the company positioned for medium-term growth but with clear short-term challenges.View all MKKGY earnings summaries
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Dr Reddy's Laboratories
                      Viatris
                      Teva Pharmaceutical
                      Takeda Pharmaceutical Company
                      Haleon PLC Sponsored ADR

                      Ownership Overview

                      <0.01%99.99%
                      Insiders
                      <0.01% Other Institutional Investors
                      99.99% Public Companies and
                      Individual Investors

                      Options Prices

                      Currently, No data available
                      ---
                      Popular Stocks